Status:

NOT_YET_RECRUITING

Psilocybin-assisted Therapy for Post-Traumatic Stress Disorder in Survivors of Intimate Partner Violence

Lead Sponsor:

University of Calgary

Collaborating Sponsors:

Vancouver Island University

University of British Columbia

Conditions:

Post Traumatic Stress Disorder PTSD

Intimate Partner Violence (IPV)

Eligibility:

All Genders

18-65 years

Phase:

PHASE2

Brief Summary

The goal of this randomized controlled trial is to evaluate the efficacy of psilocybin administered with Acceptance and Commitment Therapy (ACT) as an intervention to reduce post-traumatic stress diso...

Detailed Description

The overall objective of this study is to evaluate the efficacy of psilocybin administered with Acceptance and Commitment Therapy (ACT) as an intervention to reduce post-traumatic stress disorder (PTS...

Eligibility Criteria

Inclusion

  • Individuals of all sexes, gender identities, and ethnicities
  • Ages 19 to 65 years at the time of screening
  • At least 6 months since last IPV incident
  • A score of 1 on the Composite Abuse Scale with repetition of abusive events
  • Minimum PCL-5 score of ≥ 33
  • Limited lifetime use of serotonergic hallucinogens
  • Ability to read/write English

Exclusion

  • Severe or moderate substance use disorder other than nicotine in past 6 months
  • Lifetime diagnosis of schizophrenia or bipolar disorders (or first or second-degree relative)
  • Active suicidal ideation or serious attempt within the past 1 year.
  • Current pregnancy or nursing, trying to become pregnant
  • Any notable abnormality on ECG or routine medical blood laboratory test
  • Insulin-dependent diabetes; if taking oral hypoglycemic agent, then no history of hypoglycemia
  • Epilepsy with a history of seizures
  • Current or recent (within 12 weeks) participation in a clinical trial
  • Cognitive impairment (SLUMS score \<20)
  • Suffered a moderate/severe TBI at least once in lifetime
  • Suffered a mild TBI within the last 6 months
  • Any other circumstances that, in the opinion of the investigators, compromises participant safety
  • Not compelled to enter treatment to avoid legal consequences

Key Trial Info

Start Date :

August 1 2026

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

August 1 2029

Estimated Enrollment :

76 Patients enrolled

Trial Details

Trial ID

NCT06885996

Start Date

August 1 2026

End Date

August 1 2029

Last Update

January 6 2026

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

University of Calgary

Calgary, Alberta, Canada, T2N 2T9

2

The University of British Columbia - Okanagan Campus

Kelowna, British Columbia, Canada, V1V 1V7

3

Vancouver Island University

Nanaimo, British Columbia, Canada, V9R 5S5